Abstract
Epigenetics is key to understanding modulation of gene expression at specific stages and conditions in nervous system development and function. In epigenetic processes, a variety of enzymes contribute to modify chromatin with methyl, acetyl or other chemical marks, leading to repression or activation of the targeted gene without altering the original sequence. Aberrant activities of these epigenetic enzymes are implicated in many nervous system diseases, including neurodevelopmental disorders, brain cancer, neurodegenerative diseases, and mental illnesses. Thus, they have emerged as new targets for treating a variety of nervous system disorders. In this review, we briefly summarize the association between various epigenetic mechanisms and discuss recent progress in drug discovery efforts involving epigenetic regulators.
Keywords: DNA methyltransferase, epigenetics, glioma, histone deacetylase, histone methyltransferase, nervous system disease, neurodevelopmental disease, neurodegenerative disease
CNS & Neurological Disorders - Drug Targets
Title:Targeting Epigenetics in Nervous System Disease
Volume: 12 Issue: 1
Author(s): Ruihan Zhang, Junyan Lu, Xiangqian Kong, Lu Jin and Cheng Luo
Affiliation:
Keywords: DNA methyltransferase, epigenetics, glioma, histone deacetylase, histone methyltransferase, nervous system disease, neurodevelopmental disease, neurodegenerative disease
Abstract: Epigenetics is key to understanding modulation of gene expression at specific stages and conditions in nervous system development and function. In epigenetic processes, a variety of enzymes contribute to modify chromatin with methyl, acetyl or other chemical marks, leading to repression or activation of the targeted gene without altering the original sequence. Aberrant activities of these epigenetic enzymes are implicated in many nervous system diseases, including neurodevelopmental disorders, brain cancer, neurodegenerative diseases, and mental illnesses. Thus, they have emerged as new targets for treating a variety of nervous system disorders. In this review, we briefly summarize the association between various epigenetic mechanisms and discuss recent progress in drug discovery efforts involving epigenetic regulators.
Export Options
About this article
Cite this article as:
Zhang Ruihan, Lu Junyan, Kong Xiangqian, Jin Lu and Luo Cheng, Targeting Epigenetics in Nervous System Disease, CNS & Neurological Disorders - Drug Targets 2013; 12 (1) . https://dx.doi.org/10.2174/1871527311312010018
DOI https://dx.doi.org/10.2174/1871527311312010018 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pore-forming Peptides: A New Treatment Option for Cancer
Current Medicinal Chemistry Peptides as Tight Junction Modulators
Current Pharmaceutical Design Glioma Dynamics and Computational Models: A Review of Segmentation, Registration, and In Silico Growth Algorithms and their Clinical Applications
Current Medical Imaging Anti-Apoptotic Mechanisms of Drug Resistance in Cancer
Current Cancer Drug Targets Antiangiogenic Drugs and Tyrosine Kinases
Anti-Cancer Agents in Medicinal Chemistry Towards Drug Discovery for Brain Tumours: Interaction of Kinins and Tumours at the Blood Brain Barrier Interface
Recent Patents on CNS Drug Discovery (Discontinued) Nanomedicinal Approach of Getting Across the Brood-Brain Barrier with Nanomedicinal Nanoparticles
Current Medicinal Chemistry The Effects of Colchicum baytopiorum on Regulatory Genes of Apoptotic and Autophagic Cell Death in HeLa Cells
Current Pharmaceutical Biotechnology Urokinase-type Plasminogen Activator (uPA) and its Receptor (uPAR): Development of Antagonists of uPA / uPAR Interaction and their Effects In Vitro and In Vivo
Current Pharmaceutical Design A novel NGR-conjugated peptide targets DNA damage responses for radiosensitization
Current Cancer Drug Targets Cell-Based Assay System to Estimate the Effect of 125I Seeds on Cancer Cells: Effect of Osteopontin
Recent Patents on Anti-Cancer Drug Discovery MicroRNAs and Cancer; an Overview
Current Pharmaceutical Biotechnology Utilising Nanotechnology and Nanosystems for Treatment of Rare Diseases
Pharmaceutical Nanotechnology Nanotechnology Advances in Brain Tumors: The State of the Art
Recent Patents on Anti-Cancer Drug Discovery Synthesis and Evaluation of Heterocycles Based Chalcone Derivatives as Antiproliferative Agents
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in Oncological Submissions of Dendrimer
Current Pharmaceutical Design Anti-diabetic Drug Metformin: Challenges and Perspectives for Cancer Therapy
Current Cancer Drug Targets Cannabinoid System as a Potential Target for Drug Development in the Treatment of Cardiovascular Disease
Current Vascular Pharmacology Recent Developments in the Formulation of Nanoliposomal Delivery Systems
Current Nanomaterials Interlinking of Hypoxia and Estrogen in Thyroid Cancer Progression
Current Medicinal Chemistry